Safety and Immunogenicity of the BNT162b2 COVID-19 Vaccine in Immunocompromised Participants 2 Years and Older: Results of an Open-Label Phase 2b Study
Authors:
- Alpana WaghmareAWAlpana Waghmare
- Rucha DadheRDRucha Dadhe
- Robin KobbeRKRobin Kobbe
- Lara Danziger-IsakovLDLara Danziger-Isakov
- Eduardo SprinzESEduardo Sprinz
- Flor M. MuñozFMFlor M. Muñoz
- Juleen GayedJGJuleen Gayed
- Rohit SolanRSRohit Solan
- Oyeniyi DiyaODOyeniyi Diya
- Bisrat AbrahamBABisrat Abraham
- Ye FengYFYe Feng
- Xia XuXXXia Xu
Open Access
Abstract
Background: The BNT162b2 vaccine is safe and effective for COVID-19 prevention. BNT162b2 safety and immunogenicity have been evaluated in immunocompromised individuals in real-world observational studies, particularly in pediatric populations, but not in clinical trials. Methods: This phase 2b single-arm trial descriptively evaluated a Dose 3 (age-appropriate) BNT162b2 primary series with a Dose 4 in immunocompromised individuals 2–<5, 5−<12, 12–<18, and ≥18 years of age without a previous clinical or microbiological COVID-19 diagnosis. Primary objectives were to describe immune responses, reactogenicity, and adverse events following vaccination. Results: Out of 124 participants enrolled, 119 received Dose 3 and 90 received Dose 4. Among participants without evidence of past SARS-CoV-2 infection, neutralizing geometric mean titers (GMTs) and geometric mean fold rises (GMFRs) against the SARS-CoV-2 ancestral strain ranged from 344.6 to 1584.4 and 7.9 to 36.4 at 1 month after Dose 3 and from 1474.0 to 4157.9 and 31.0 to 95.6 at 1 month after Dose 4, respectively, across age groups. Among participants with or without evidence of past infection, GMTs and GMFRs ranged from 787.1 to 2940.6 and 9.6 to 54.3 at 1 month after Dose 3 and from 1031.3 to 13,457.1 and 9.1 to 220.0 at 1 month after Dose 4. Percentages of participants with or without evidence of past SARS-CoV-2 infection achieving seroresponse ranged from 50.0 to 92.9% at 1 month after Dose 3, and from 75.0 to 100% and 33.3 to 100.0% at 1 and 6 months after Dose 4 across age groups, respectively. No new safety signals were identified. Conclusions: BNT162b2 was immunogenic, increasing GMTs in immunocompromised individuals ≥2 years old, particularly after Doses 3 and 4. GMT increases were generally similar across age groups and disease subsets. Three or four BNT162b2 doses had a favorable risk-benefit profile in this population.Keywords
Funding Information
- Pfizer
- BioNTech
This publication has 35 references indexed in Scilit:
- Burden of SARS‐CoV‐2 infection prior to vaccine eligibility among immunocompromised children aged 1–11 years at a pediatric tertiary referral hospital in Toronto, CanadaPediatric Blood & Cancer, 2024
- Immunogenicity of third dose COVID-19 vaccine strategies in patients who are immunocompromised with suboptimal immunity following two doses (OCTAVE-DUO): an open-label, multicentre, randomised, controlled, phase 3 trialThe Lancet Rheumatology, 2024
- Immunocompromised individuals are at increased risk of COVID‐19 breakthrough infection, hospitalization, and death in the post‐vaccination era: A systematic reviewImmunity, Inflammation and Disease, 2024
- Humoral and cellular response to the COVID-19 vaccine in immunocompromised childrenPediatric Research, 2022
- Safety of and antibody response to the BNT162b2 COVID-19 vaccine in adolescents and young adults with underlying diseaseJournal of Infection and Chemotherapy, 2022
- Response to additional COVID-19 vaccine doses in people who are immunocompromised: a rapid reviewThe Lancet Global Health, 2022
- The SARS‐CoV‐2 omicron wave is indicating the end of the pandemic phase but the COVID‐19 will continueJournal of Medical Virology, 2022
- SARS-CoV-2 anti–spike antibodies after vaccination in pediatric heart transplantation: A first reportThe Journal of Heart and Lung Transplantation, 2021
- COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responsesNature, 2020
- Susceptibility to SARS-CoV-2 Infection Among Children and Adolescents Compared With AdultsJAMA Pediatrics, 2020